4th Immuno Oncology Master Course- 14th-16th May 2020
Program Director: Dr. TP Sahoo & Dr. Purvish Parikh
Please see the schedule below.
Sponsored Session:
A- Intas: Docetaxel Aqualip in HSPC - Chandan Das
B- Dr Reddy's: Tackling Common Toxicities - Sandeep Batra
C- Novartis: Survival in BRAF Mutated Melanoma - Bivas Biswas
D- OncoStem: Immunotherapy Options for Breast Cancer - Chirag Desai
E- Novartis: Overall Survival in HR+ HER2-aBC - Joydeep Ghosh
F- J & J: Treatment Sequencing in Multiple Myeloma - Hemant Malhotra
G- Astra Zeneca: How to Manage a Stage-III NSCLC Patient - Kumar Prabhash
H- Biocon: Mgmt of Advance Head and Neck Cancer - Neera Gupta
Joint Session (IASCO, ICON & ISMPO): Elderly in Oncology Therapy - Amish Vora
Session 1 - Are All IO Drugs The Same:
1. Why CPS in Some and TPS in Others? - Nikhil Ghadyalpatil
2. Biomarker Update - PDL1, MSI, Others - Chirag Desai
3. Are All IO Drugs the Same - Hemant Malhotra
Session 2 - Lessons From Melanoma:
1. Lessons from BRAF Inhibition - Prasad Narayanan
2. IO in Melanoma - Rejiv Rajendranath
3. Lessons from Melanoma - Raghunadhrao Digumarti
Session 3- Head & Neck Immunotherapy:
1. Role of CPS in SCCHN - Ghanashyam Biswas
2. Immunotherapy- RR as Single Agent - Kumar Prabhash
3. What were/are the Standards in IO - Amit Agarwal
Session 4 - Breast Cancer & IO:
1. IO in Early Stage TNBC - Prashant Mehta
2. Metastatic Breast Cancer - Amit Rauthan
3. Breast Cancer and Immunotherapy - Govind Babu
Session 5 - Genitourinary & IO:
1. IO in Renal Cell Cancer - Vineet Talwar
2. IO in Urothelial Malignancies - Manish Singhal
3. Immuno Oncology & Genito Urinary Cancers - AK Vaid
Session 6 - NSCLC and IO (Part 1):
1. Single Agent IO vs IPI/Nivo Combination - Vikas Talreja
2. Spoilt for Choice in 1st Line - Ullas Batra
3. Immuno Oncology and NSCLC - R Rangarao
Session 7 - Panel Discussion:
MedicoLegal Issues - Purvish Parikh
Session 8 - Lung Cancer & IO (Part 2):
1. Bevacizumab in Advanced NSCLC - Ankur Bahl
2. Role of Consolidation With IO - Randeep Singh
Session 9 - CRC & IO:
1. MDR Monitoring in CRC Patients - Vamshi Krishna
2. Mx of First Line in Frail Patients - Shyam Aggarwal
3. CRC and IO - Shekhar Patil
Session 10 - Other GI Malignancies & IO:
1. Mgmt of Second Line Advanced Ca Stomach - Rahul Sud
2. IO vs TKI in HCC - T Raja
3. Other GI Malignancies & IO - Pankaj Goyal
Session 11 - Panel Discussion:
IO Rx During Crisis- Chaturbhuj Agrawal